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Abstract: Over the last several decades the idea that adenosine (Ado) plays a role in sleep control was postulated due in 
large part to pharmacological studies that showed the ability of Ado agonists to induce sleep and Ado antagonists to de-
crease sleep. A second wave of research involving in vitro cellular analytic approaches and subsequently, the use of neu-
rochemical tools such as microdialysis, identified a population of cells within the brainstem and basal forebrain arousal 
centers, with activity that is both tightly coupled to thalamocortical activation and under tonic inhibitory control by Ado. 
Most recently, genetic tools have been used to show that Ado receptors regulate a key aspect of sleep, the slow wave ac-
tivity expressed during slow wave sleep. This review will briefly introduce some of the phenomenology of sleep and then 
summarize the effect of Ado levels on sleep, the effect of sleep on Ado levels, and recent experiments using mutant mouse 
models to characterize the role for Ado in sleep control and end with a discussion of which Ado receptors are involved in 
such control. When taken together, these various experiments suggest that while Ado does play a role in sleep control, it is 
a specific role with specific functional implications and it is one of many neurotransmitters and neuromodulators affecting 
the complex behavior of sleep. Finally, since the majority of adenosine-related experiments in the sleep field have focused 
on SWS, this review will focus largely on SWS; however, the role of adenosine in REM sleep behavior will be addressed. 
PHENOMENOLOGY OF SLEEP 
  Sleep may be phenomenologically characterized by four 
criteria: a species specific posture, characteristic changes in 
the  electroencephalogram  (EEG),  an  increase  in  response 
threshold  to  environmental  stimuli,  and  quick  reversibility 
[76]. Using these criteria, sleep can be further divided into 
two  main  stages,  slow  wave  sleep  (SWS)  and  rapid  eye 
movement sleep (REM). In mammals, EEG and electromy-
ogram (EMG) activity is sufficient to determine sleep/waking 
state. During waking, the EEG is dominated by low ampli-
tude, high frequency activity, with high muscle activity ap-
parent in the EMG. During SWS, EEG activity is dominated 
by  high  amplitude,  low  frequency  activity  known  as  slow 
wave  activity  (SWA,  0.5-4.5  Hz  oscillation  in  membrane 
potential), with little EMG modulation. During REM sleep, 
EEG activity is dominated by low amplitude, high frequency 
activity  similar  to  that  of  waking,  with  EMG  modulation 
absent except for the occasional muscle twitch. Sleep behav-
ior is controlled by circadian and homeostatic mechanisms, 
with circadian rhythms influencing the time of day in which 
sleep expression is likely to occur and homeostatic mecha-
nisms providing a cumulative ‘time awake’ input which re-
sults  in  increasing  sleep  drive  with  increasing  amounts  of 
waking. Examples of EEG traces for each of these states are 
shown in Fig. (1). The remainder of this review will focus in 
large  part  on  SWS  because  Ado  has  been  most  closely 
linked, both  theoretically and  experimentally,  to this  sleep 
stage and to the EEG activity that characterizes it, SWA. 
BRAIN REGIONS INVOLVED IN SLEEP BEHAVIOR 
  The hunt to identify the brain regions sufficient and nec-
essary for the induction and maintenance of sleep behavior  
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Fig. (1). Raw electroencephalograph and electromyography exam-
ples of waking, SWS, and REM sleep from a C57/BL6 mouse. EEG 
signals were recorded from screw electrodes overlying the cortex, 
while EMG signals were recorded from panel electrodes from the 
dorsal neck muscle. Each trace shows a 10 sec epoch. The y-axis is 
set at 250 µv. 
has been ongoing for many years. This search has been met 
with limited success because while there are many brain ar-
eas that show sleep modulated activity, no single brain area 
is necessary for sleep. Numerous brain areas implicated in 
sleep control have been lesioned, however, if an animal sur-
vives,  it sleeps,  though sometimes sleep returns only after 
several weeks of recovery [38, 73]. Currently there are sev-
eral brain  areas  that are thought  to be  important for sleep 
control,  including:  mesopontine  tegmentum  [62],  hypo-
thalamus [66], and basal forebrain [27]. In vitro and in vivo 
studies have determined the effect of Ado agonists and an-
tagonists  on  activity  within  these  sleep  centers.  In  the Adenosine and Sleep  Current Neuropharmacology, 2009, Vol. 7, No. 3    239 
mesopontine  tegmentum,  Ado  agonists  inhibit  cholinergic 
neurons [50] and reduce evoked glutamatergic EPSCs and 
GABAergic IPSCs [2]. The mesopontine tegmentum is part 
of the cholinergic arousal system so decreasing activity in 
these cholinergic, glutamatergic, and GABAergic cells would 
serve to facilitate sleep and the thalamocortical neural activ-
ity of burst firing that underlies the slow wave activity in the 
EEG during slow wave sleep [45, 50]. In the hypothalamus, 
Ado agonists inhibit the wake-active hypocretin/ orexin neu-
rons [33] and disinhibit or excite the sleep-active neurons in 
the  preoptic/anterior  hypothalamic  area  and  ventrolateral 
preoptic area [11, 19, 39, 40]. Finally, in the basal forebrain, 
Ado  agonists  inhibit  wake-on  neurons  [1,  67].  The  basal 
forebrain has been the focus of the hypothesis that Ado is 
involved in sleep homeostasis due to the finding that the ba-
sal forebrain was the only cholinergic arousal center to show 
sustained, elevated levels of Ado after 6 hrs of sleep depriva-
tion [44]. Nonetheless, the failure to show a similar elevation 
in the cholinergic brainstem center may have resulted from 
the small size of nuclei within the brainstem and the rela-
tively large size of the microdialysis probe. Together, direct 
inhibition of wake-active neurons and their inhibition through 
the excitation of sleep-active neurons may increase the prob-
ability that sleep with high slow wave  activity will occur. 
Ado  may  contribute  to  this  process  through  inhibition  of 
arousal  centers,  as  well  as,  through  inhibition  of  thalamo-
coritical  systems  providing  excitatory  drive  to  these  same 
centers.  
ORIGIN OF EXTRACELLULAR ADO 
  Ado levels are influenced by neuronal activity. Ado is a 
secondary by-product of the breakdown of ATP and cAMP. 
When  ATP  is  co-released  with  neurotransmitters,  ecto-
nucleotidases in the extracellular space can rapidly dephos-
phorylate ATP, ADP, and AMP into Ado [15]. Ado can also 
be released into the extracellular space by two equilibrative 
nucleoside transporters.  
  ATP release from astrocytes also contributes to extracel-
lular levels of Ado that have a powerful modulatory effect on 
synaptic transmission [43]. The role of this astrocyte-derived 
Ado in sleep/waking homeostasis was recently investigated. 
Astrocytic  transmitter  release  was  prevented  in  a  mutant 
mouse using a conditional knockout of the synaptobrevin II 
protein  involved  in  exocytosis  that  was  expressed  only  in 
astrocytes [22]. These mutant mice spent the same amount of 
time  in  waking,  SWS,  and  REM  sleep  as  wildtype  mice, 
however mutant mice showed reduced SWA and a decrease 
in recovery sleep following sleep deprivation.  
INFLUENCE  OF  ADO  LEVELS  ON  SLEEP  AND 
WAKEFULNESS 
  In the mid to late 1900s it was found that Ado agonists 
decrease  wakefulness  and  increase  sleep  [10,  17,  23,  46]. 
Furthermore,  such  agonists  also  tend  to  increase  deeper 
stages of SWS at the expense of lighter SWS [49], with deep 
and  light  stages  defined  on  the  basis  of  amount  of  slow 
waves, greater than 50% per epoch versus less than 50% per 
epoch, respectively. Additionally, Ado agonists increase SWA 
or delta power [6, 61] as assessed by Fast Fourier Transform 
(FFT) analysis. SWA power reflects the relative amount of 
the EEG signal that falls within the SWA band (0.5-4.5 Hz).  
  Conversely, Ado receptor antagonists increase wakeful-
ness and decrease sleep [61, 72, 75]. One of the most com-
monly used pharmacological agents, caffeine, is a nonselec-
tive Ado antagonist which primarily acts at two of the four 
Ado  receptor  subtypes,  the  A1R  and  A2aR  to  influence 
sleep/waking  behavior.  The  estimated  daily  intake  of  caf-
feine in American citizens is about 280 milligrams, which is 
above the functional dose for decreasing sleep [29, 31]. Fur-
thermore,  caffeine  and  other  antagonists  decrease  SWA 
within sleep as well [31, 32], an effect which is modulated 
by  caffeine-sensitivity  in  humans  [52].  Both  agonists  and 
antagonists affect sleep and SWA when given systemically 
[49, 61, 75] or within the brain [6, 39, 41, 46, 70]. Some of 
the  biggest  effects  are  seen  when  Ado  is  injected  directly 
into the basal forebrain [4, 46]. This point will be discussed 
in detail in the next section.  
  In addition to agonists and antagonists, other compounds 
that alter endogenous Ado levels have been shown to modify 
sleep and SWA within sleep. These compounds include an 
Ado kinase inhibitor that increases Ado levels by inhibiting 
the phosphorylation of Ado to AMP, Ado deaminase inhibi-
tors, which increase Ado levels by inhibiting the breakdown 
of Ado into inosine, and transport inhibitors, which blocks 
the transport of Ado into the cell. Ado kinase, deaminase, 
and transport  inhibitors decrease wakefulness  and increase 
sleep [45, 47, 48]. The Ado kinase inhibitor also increases 
SWA within SWS [47]. Furthermore, recent genetic screen-
ing experiments have shown that a genetic variant of Ado 
deaminase that decreases metabolism of Ado to inosine, re-
sults in an increase in deep SWS and SWA [53]. 
  Evidence from extracellular injection of antisense mRNA 
is consistent with the idea that the expression of Ado recep-
tor levels influence sleep/waking behavior. Injection of an-
tisense deoxyoligonucleotides against Ado receptor mRNA 
into the basal forebrain, increases waking, while decreasing 
SWS and SWA [69]. Under conditions of recovery from 6 hr 
sleep deprivation, changes in waking, sleep, and SWA were 
even more pronounced. However some caution in the inter-
pretation  of  these  results  is  needed  because  of  the  well 
documented  non-specific  and  “off-target”  effects  of  an-
tisense injections. We did not observe any change in SWS 
duration  with  localized  knockout  of  the  A1R  [technique  
described in 58] in either the forebrain or the brainstem cho-
linergic arousal centers using an AAV-vector mediated local-
ized expression of Cre recombinase together with a floxed 
A1R gene [unpublished observations, Ronan, P. and Greene, 
R.W., 2002]. Based on these observations we concluded that 
A1Rs on pre-synaptic terminals are especially important for 
the SWS effects of localized injections of either A1R ago-
nists [46] or blockers of Ado re-uptake [45] since these pre-
synaptic receptors would not be affected by localized knock-
out of the A1R gene (Ronin and Greene unpublished obser-
vations). In fact, these findings led us to use a conditional 
knockout  of  the  A1R  that  would  affect  most  of  the  pre-
synaptic terminals that synapse onto neurons of the choliner-
gic arousal centers [7] as described below.  
  Together the evidence from Ado agonists, antagonists, an 
Ado kinase inhibitor, Ado deaminase inhibitors, and an Ado 
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creases sleep, while decreasing Ado levels increases wake-
fulness.  
INFLUENCE  OF  BEHAVIORAL  STATE  (WAKE-
FULNESS AND SLEEP) ON ADO LEVELS WITH AN 
EMPHASIS ON THE BASAL FOREBRAIN 
  As  mentioned  in  a  previous  section,  injection  of  Ado 
agonists and antagonists into the brain, and specifically into 
the basal forebrain [46, 65], modify neural activity and ulti-
mately influence behavioral state, arguing that modification 
of Ado levels is sufficient to alter sleep/waking state. This 
raises the question of whether sleep/waking state influences 
Ado  levels.  If  Ado  is,  in  fact,  involved  in  controlling 
sleep/waking state, then Ado levels should rise during wak-
ing and decrease during subsequent sleep. 
  During  sleep  Ado  levels  decrease  in  the  cortex,  basal 
forebrain, hypothalamus, and brainstem [44, 45]. When ani-
mals are kept awake for extended periods of time (sleep dep-
rivation), however, levels of Ado continue to rise or are sta-
ble only in one of these brain regions, the basal forebrain [4, 
44]. This piece of evidence lead to a modification of the hy-
pothesis that Ado is involved in sleep/waking control, to the 
hypothesis that Ado acts specifically within the basal fore-
brain  to  influence  sleep/waking  state.  However,  as  previ-
ously mentioned this lack of evidence may, at least in part 
reflect  the  technical  limitations  of  the  microdialysis  tech-
nique used to assess these changes. Evidence from in vitro 
studies  suggests  that  in  the  brainstem  cholinergic  arousal 
center,  persistent,  increased  synaptic  glutamate  release 
within  the  range  of  what  may  be  expected  during  waking 
will gradually increase Ado levels in the microenvironment 
of  the  synapse  and  this  in  turn,  will  feedback  to  decrease 
glutamate through activation of pre-synaptic A1Rs [9]. This 
same kind of effect is likely to occur in other brain regions 
involved in sleep induction and maintenance and their target 
regions as well. Ado levels progressively rise during waking, 
inhibiting  cholinergic  and  noncholinergic  neurons,  thereby 
decreasing  acetylcholine  release  which  underlies  the  cho-
linergic arousal system [50]. Furthermore, decreased acetyl-
choline release facilitates the transition of fast spiking to burst 
pause firing in thalamocortical neurons [36], which serves to 
synchronize  neural  firing,  resulting  in  the  high  amplitude, 
low frequency activity that underlies SWA during sleep.  
  A recent controversy developed when Blanco-Centurion 
and  colleagues  tested  the  hypothesis  of  behavioral  state 
modification by Ado’s action on cholinergic neurons in the 
basal forebrain. They selectively lesioned cholinergic basal 
forebrain neurons using the cholinergic-selective toxin 192 
immunoglobulin-saporin  (IgG-saporin)  [8].  However,  they 
found that although Ado levels did not increase in these le-
sioned animals, they still had normal sleep homeostasis. This 
finding challenged the belief that Ado modulated behavioral 
state by acting on cholinergic neurons in the basal forebrain. 
However,  subsequent  research  using  IgG-saporin  has  rein-
stated the idea that cholinergic neurons in the basal forebrain 
are  involved  in  the  Ado  regulation  of  sleep  homeostasis. 
Two groups (McCarley  and Semba) directly  injected IgG-
saporin into the basal forebrain to destroy cholinergic neu-
rons and found that lesioned animals displayed significantly 
less  rebound  sleep  in  response  to  acute  sleep  deprivation, 
indicating  abnormal  sleep  homeostasis  [28,  30].  Addition-
ally, the McCarley group also used i.c.v. IgG-saporin injec-
tions  to  decrease  basal  forebrain  cholinergic  cell  numbers 
and  found  that  two  weeks  after  injection,  animals  showed 
normal sleep homeostasis in response to sleep deprivation, 
while three weeks after injection, animals displayed abnor-
mal  sleep  homeostasis  [28].  Therefore,  it  is  likely  that 
Blanco-Centurion may not have found an effect of choliner-
gic cell lesions on sleep homeostasis because they measured 
the  effect  of  sleep  deprivation  on  homeostasis  two  weeks 
following i.c.v. injection.  
ADO  RECEPTORS  INVOLVED  IN  MODULATING 
SLEEP HOMEOSTASIS 
  One question that has fueled several recent experiments 
is:  which  Ado  receptor(s)  underlie  the  effects  of  Ado  on 
sleep/waking homeostasis? There are currently 4 known Ado 
receptors, A1R, A2aR, A2bR and A3R. For sleep/waking ho-
meostasis the A1Rs and A2aRs have received the most atten-
tion due to their expression pattern in the nervous system, the 
availability of selective agonists and antagonists and selec-
tive molecular lesions of genes encoding the receptor sub-
types. A1R are expressed at high levels throughout the brain, 
particularly in the cortex, hippocampus, thalamus and cere-
bellum [14, 51]. A2aRs are expressed most strongly in  the 
striatum [18]. Using RT-PCR, Dixon and colleagues found 
low levels of A2aR , A2bR, and A3R ’s expressed throughout 
the brain [14].  
  A1R agonists and antagonists modify sleep/waking when 
given peripherally [49, 72] and centrally [34, 39, 68]. A2AR 
agonists  and  antagonists  also  modify  sleep/waking  when 
given peripherally [61, 75] and centrally [12, 24, 34, 39, 56, 
59]. Additionally, in humans, A1Rs are upregulated follow-
ing sleep deprivation [16], while in rodents A1Rs are upregu-
lated in the basal forebrain following sleep deprivation [3].  
  A1Rs are Gi-coupled and generally considered inhibitory, 
while A2aR s are Gs coupled and considered excitatory. A1Rs 
may modify sleep/waking by direct and indirect mechanisms 
including: inhibition of cholinergic neurons in the mesopon-
tine tegmentum that are part of the cholinergic arousal sys-
tem [50], inhibition wake-active hypocretin/orexin neurons 
in the lateral hypothalamus [33] and wake-active neurons in 
the basal forebrain [1, 67], and disinhibition of sleep-active 
neurons in the preoptic/anterior hypothalamic area and ven-
trolateral preoptic area [11, 40]. 
  Mechanisms of sleep/waking homeostasis for A2ARs in-
clude: inhibition of histaminergic neurons [24], excitation of 
sleep-active  neurons  in  the  ventrolateral  preoptic  nucleus 
[19], and modulation of acetylcholine release in the pontine 
reticular formation [12], resulting in increased time in SWS 
and REM sleep. Additionally, A2AR agonists increase SWS 
and REM sleep when injected into the prostaglandin D2 sen-
sitive zone under the basal forebrain, while injection of A2AR 
antagonists into the same zone decreases prostaglandin D2-
induced SWS [57].  The  most dominant A2aR effect in ro-
dents may be indirect through activation of inhibitory motor 
circuits in  the striatum, where  most of  the A2aR s are ex-
pressed. This may explain the robust stimulant effects of the 
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knock out animals, while A2aR knock out animals showed 
much subtler effects at higher doses of caffeine [25]. Loco-
motor activity is increased in these animals and locomotion 
is a powerful arousing stimulus in rodents. In contrast to the 
reported adenosine antagonists arousing effects being medi-
ated through A2aR, injection of an A2aR antagonist into the 
ventral striatum increased time in SWS and REM sleep, as 
well as, decreased FOS expression within wake-active orexin 
neurons in the hypothalamus [55] which provides a mecha-
nism to control sleep behavior that may not be locomotion-
specific. Alternatively, this effect may have been mediated 
through a non-specific action of the A2aR antagonist to cause 
phosphodiesterase inhibition. 
  Recent  experiments  have  used  genetic  manipulation  to 
determine whether A1Rs or A2aR s  are responsible for the 
effect  of  Ado  on  sleep/waking  homeostasis.  Stenberg  and 
colleagues used constitutive A1R knockout mice and found 
normal  sleep/homeostasis  and  SWA  in  response  to  sleep 
deprivation by gentle handling [63]. In contrast, our lab, us-
ing conditional A1R knockout mice (a Cre-loxP based sys-
tem  using  a  CAMKII  promoter  for  the  Cre  recombinase 
gene), found a significant decrease in SWA in response to 
both acute and chronic sleep restriction [7]. For acute sleep 
restriction, we used a slowly moving treadmill (~ 3 cm/sec) 
to enforce waking for 4 hrs followed by 2 hrs of unrestricted 
behavior. For chronic sleep restriction, this 6 hr cycle (4 hrs 
treadmill on, 2 hrs treadmill off) was repeated 8 times across 
48 hrs. The use of the treadmill to enforce waking is a poten-
tially less variable method of sleep restriction since, unlike 
gentle handling, in which animals are given novel objects on 
an “as needed” basis in which arousal state could fluctuate, 
the treadmill is constantly “on” and the animals are forced to 
move  at  a  relatively  constant  rate.  Interestingly,  the  mice 
with intact A1Rs, compensated for the sleep restriction with 
increased SWA but unchanged SWS duration (SWS duration 
was compared to the same time period under non-sleep re-
stricted conditions). The compensatory SWA response in the 
A1R knockout mice was largely missing. These conditional 
knockout mice were able to express SWA during SWS but 
were  unable  to  increase  SWA  when  sleep  was  restricted. 
Thus, the A1R receptor is involved in the homeostatic modu-
lation of SWA, but is not necessary for SWA expression, in 
other words, while the A1R is not necessary for the expres-
sion of SWA (knockout mice still show EEG activity in the 
SWA band), the A1R does play a role in the modulation of 
SWA  (knockout  mice  show  significantly  less  sleep-
deprivation induced SWA). 
  As for the effect of A2aRs on sleep homeostasis, Urade 
and collegues used A2aR knockout mice and found a lack of 
modulation of sleep/waking in response to injection of A1R 
agonists into the lateral ventricle [71], suggesting that A2aRs 
underlie the ability of Ado to modulate sleep/waking. Nega-
tive results are difficult to interpret in this case and may have 
resulted from an insufficient concentration of A1R agonist at 
the most relevant receptor sites, including pre-synaptic exci-
tatory terminals onto basal forebrain neurons. In a separate 
report, this group showed that A2aR knockout mice have ab-
normal  autonomic  control  during  REM  sleep  compared  to 
wildtype controls [54]. 
A1R  ACTIVATION  AND  THE  FUNCTION  OF  SWA 
OF SLEEP 
  The loss of A1Rs in the  CNS resulted in a remarkably 
specific sleep phenotype, characterized by the absence of the 
compensatory increase in SWA in response to sleep restric-
tion. Although there was a significant decrease in SWA ex-
pression in A1R knockout mutants under baseline conditions, 
the effect size was small. Under baseline conditions, the mu-
tants  could  perform  a  working  memory  task  equally  well 
compared to their matched wild phenotype littermates. When 
both groups of mice were challenged with sleep restriction, 
only the mutants showed a reduced performance in associa-
tion with a loss of compensatory SWA response [7]. 
  The working memory task places particular demands on 
prefrontal  cortical  circuits  that  involve  sustained  neuronal 
activity, thought to reflect active, short term encoding of the 
working memory [20]. The selective loss of compensatory 
SWA may have  compromised  the ability of  the prefrontal 
cortical circuits to generate and sustain the needed neuronal 
activity for effective working memory dependent perform-
ance. This is a different kind of deficit than that involving 
consolidation of memory as working memory is short lasting 
(less than 10’s of seconds) and does not involve consolida-
tion at all. Our findings suggest that with mild sleep restric-
tion,  working  memory  function  may  be  more  sensitive  to 
compensatory SWA loss than hippocampal dependent mem-
ory and its consolidation [7]. 
A1R ACTIVATION LEADS TO INCREASED SWA AT 
THE CELLULAR  LEVEL IN THALAMOCORTICAL 
NEURONS 
  Several  investigators  have  shown  that  modulation  of 
A1Rs influence SWA without modifying sleep time. Activa-
tion  of  A1Rs  can  enhance  SWA  through  two,  additive 
mechanisms; one indirect  that involves the brainstem cho-
linergic arousal system and the other through direct actions 
on thalamic and cortical neurons. Fig. (2) shows an illustra-
tion of both the indirect and direct sites of action and effects 
of Ado on SWA. The indirect Ado action results from high 
waking (and REM sleep) cholinergic tone in thalamocortical 
neurons, relative to the low tone during SWS [35, 74]. This 
tone is in turn modulated in the brainstem and basal fore-
brain cholinergic arousal centers in a state specific manner 
by A1Rs [21, 45, 50]. Acetylcholine inhibits slow frequency 
activity in thalamocortical neurons [13, 37, 64], so inhibition 
of brainstem cholinergic neurons via A1Rs during SWS al-
lows the expression of slow wave activity.  
  The direct effect of A1R activation to facilitate SWA of 
thalamic and cortical neurons is due to a combination of in-
creased GIRK channel conductance and decreased hyperpo-
larization activated current and a relative functional deaffer-
entation resulting from pre-synaptic inhibition (as shown in 
Fig. 3). In vitro circuit analysis has shown that Ado will en-
hance slow oscillations of single neurons in the absence of 
other modulatory input [42]. Localized increase of Ado can 
induce these post-synaptic effects and when combined with 
local  pre-synaptic  A1R  activation  to  reduce  afferent  input, 
and can increase SWA measured with local field recordings 
as demonstrated by localized blockade of Ado uptake with 242    Current Neuropharmacology, 2009, Vol. 7, No. 3  Bjorness and Greene 























Fig. (2). A. Indirect A1R -mediated modulation SWA. Projections from the brainstem reticular formation cholinergic arousal center to the 
thalamus and from basal forebrain cholinergic arousal center to the cortex and thalamus mediate the cholinergic tone. During waking, cho-
linergic tone is high, resulting in a desynchronized, high frequency cortical EEG (middle trace), as is monoaminergic tone (not shown). Dur-
ing REM sleep only cholinergic tone is high in association with a desynchronized EEG, similar to that observed during waking. The desyn-
chronized activity is due in part to the cholinergically induced depolarization of thalamic and cortical neurons facilitating synaptically respon-
sive non-bursting spiking patterns (bottom trace). During SWS, cholinergic tone is decreased due, in part to increased adenosine mediated 
inhibition of cholinergic center arousal neurons. The emergence of synchronized, low frequency cortical EEG (middle trace) requires this 
decreased activity in the cholinergic arousal centers of the forebrain and brainstem, allowing hyperpolarization of thalamic and cortical neu-
rons. This is a necessary condition for burst-pause oscillatory firing of thalamic and cortical neurons (bottom trace). The thalamic neuron 
recordings were made in vitro, under control, waking-like conditions (bottom left) and in the presence of adenosine to approximate SWS-like 
conditions (modified with permission from [42]).  
B. Activation of A1Rs can directly facilitate SWA. Ado hyperpolarizes thalamic and cortical neurons by increasing potassium conductance 
through the GIRK channel and by decreasing the Ih current, which facilitates burst-pause firing at the expense of single spikes [42]. Both these 
changes also reduce cell conductance at the threshold for burst generation providing an additional facilatory effect on bursting. These effects 
may be synchronized by the thalamocortical- thalamo-reticular circuits to generate the high amplitude SWA observed during sleep. Adenosine and Sleep  Current Neuropharmacology, 2009, Vol. 7, No. 3    243 
 
nitrobenzylthioinoside [45]. It is reasonable to suggest that, 
just as with brainstem arousal neurons [9], increased synaptic 
activation of NMDARs during waking in the thalamocortical 
system will slowly increase local Ado concentration to di-
rectly enhance SWA in localized thalamocortical circuits. In 
fact  asymmetric  increases  in  SWA  activity  have  been  ob-
served in association with asymmetric use-dependent activity 
during waking [26].  
  The modulation of SWA in a use-dependent fashion is a 
key prediction of the hypothesis that sleep serves as  a re-
storative function for the brain. Benington and Heller posited 
that  the  increased  release  of  adenosine  that  occurs  due  to 
waking activity, works through A1Rs to facilitate the expres-
sion of SWA, which allows for the glycogen stores, depleted 
during waking, to be replenished during sleep [5]. Recently 
Pack  and  colleagues  reviewed  research  that  supports  the 
overall hypothesis and have included additional metabolic-
factors, besides Ado, that may play a role in energy restora-
tion during sleep [60]. Finally, the use of A1R knockout ani-
mals that show reduced SWA following sleep deprivation [7] 
and  the  use  of  a  mutant  mouse  with  inhibited  astrocytic-
release of adenosine [22] indicate that adenosine is an impor-
tant factor controlling SWA expression. Additionally, these 
studies show that increased SWA expression during recovery 
sleep following sleep deprivation is important for cognitive 
performance [7], but increased SWA pressure during waking 
impairs recognition memory [22]. 
CONCLUDING REMARKS 
  There is ample evidence that Ado plays a role in regulat-
ing sleep/waking behavior, as well as, SWA. Together this 
evidence suggests that both A1Rs and A2aRs act in various 
areas of the brain to decrease neural activity and facilitate 
sleep, although the role of the A2aR may be indirect via the 
striatal locomotor systems. A1Rs primarily act to both reduce 
cholinergic tone and, in thalamocortical systems, to facilitate 
cellular oscillations at SWA frequency in response to sleep 
loss. Gene deletion of CNS A1Rs prevents the compensatory 
SWA enhancement when sleep is restricted, in association 
with reduced cognitive performance. This suggests a func-
tional role for A1R mediated compensatory SWA activity to 
maintain normal cognitive performance.  
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